
Leading pharma companies, such as Biogen, CSL Seqirus, Eli Lilly, Grifols, GSK, Merck, Pfizer, and Novo Nordisk, are taking advantage of the state’s highly skilled talent pool.

A breadth of products is manufactured in North Carolina, spanning established and new technologies. This includes treatments for diabetes, plasma-derived proteins, gene and cell-based therapies, monoclonal antibodies, vaccines and industrial enzymes.

Contract development and manufacturing organizations, such as FUJIFILM Diosynth Biotechnologies, KBI Biopharma, Resilience and Thermo Fisher Scientific, also manufacture a range of products for their clients.

Talent
North Carolina has built a substantial biopharma manufacturing talent base with 32,000 workers. With a full continuum of complementary training programs, the state can meet the growing demand for skilled workers.

NCBiolImpact, a unique public-private partnership, coordinates a full continuum of complementary training programs to fuel the talent pipeline. Partners include:
- North Carolina State University’s Biomanufacturing Training and Education Center
- North Carolina Central University’s Biomanufacturing Research Institute and Technology Enterprise
- Eastern Region Pharma Center
- North Carolina Pharmaceutical Services Network
- North Carolina Community College System’s BioNetwork

Together, they have created a world-class, hands-on training system delivering job-ready talent.

A Thriving Ecosystem
Biopharma manufacturing companies benefit from the state’s collaborative life sciences ecosystem, specialized organizations, and top-tier universities.

For the past 40 years, the North Carolina Biotechnology Center has initiated programs and coordinated resources to help biopharma companies thrive and grow. NCLifeSci hosts the Biotech Manufacturers Forum, where companies share information and create solutions for collective challenges.

Local organizations participate in National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) projects to advance innovation.

Favorable Business Climate
North Carolina has lower business operating costs compared to other leading life sciences hubs. The corporate income tax, currently at 2.5%, will decrease to 0% by 2030. The state has a favorable legal and regulatory environment, as well as plenty of land for future growth.
Global pharmaceutical giant **Eli Lilly and Company** committed to invest nearly $2 billion in North Carolina. In 2020, the company announced plans to build its first manufacturing plant in Research Triangle Park (RTP) with a $474 million investment, creating 462 new jobs. In 2022, Lilly announced an additional $939 million investment in a new pharmaceutical manufacturing facility in Concord, creating nearly 600 jobs. In 2023, Lilly announced yet another investment of $450 million, an add-on to its RTP pharmaceutical manufacturing campus, with 100+ new jobs.

In April 2024, global CDMO **FUJIFILM Diosynth Biotechnologies** announced it will invest $1.2 billion to double the size of its Holly Spring manufacturing facility, adding 680 jobs. This is in addition to the $2 billion, 725 job investment the company announced in March 2021 for the same site. Once completed, it will be the largest end-to-end cell culture CDMO facility in North America.

North Carolina is taking the lead in manufacturing new gene- and cell-based therapies as regulatory approvals are achieved.

- **AskBio**’s adeno-associated virus-based portfolio of preclinical and clinical-stage therapies, as well as its manufacturing capabilities, were acquired by Bayer in a deal worth up to $4 billion. This homegrown company turned gene therapy leader is currently developing gene therapies for six diseases.

- Durham-based **Novartis Gene Therapies** is producing Zolgensma, its FDA-approved gene therapy for spinal muscular atrophy, as well as products currently in the clinic.

- In Raleigh, **Cellectis** manufactures its portfolio of UCART drug products, including gene-editing technologies and cell therapies to treat cancers of the blood, myeloid, and lymphatic system. In 2022, the company announced the first U.S. patient received a dose of its UCART22 allogeneic CAR T cell therapy product candidate, which was manufactured in North Carolina.

From talent to training partners, from a collaborative ecosystem to a business-friendly climate, the state has what you need to accelerate your products to market. Let NCBiotech be your partner in finding the ideal place to grow your company.

**Accelerate Your Success. All in North Carolina.**

**North Carolina Biotechnology Center**

Laura Rowley, Ph.D., vice president, life sciences economic development (laura_rowley@ncbiotech.org) (984) 439-5480
Christian Brown, MPA, director, life sciences economic development (christian_brown@ncbiotech.org) (919) 549-8867
Martie Jones, associate director, life sciences economic development (martie_jones@ncbiotech.org) (919) 252-4123

15 T.W. Alexander Drive | Research Triangle Park, NC 27709-3547 | ncbiotech.org
Asheville ∙ Charlotte ∙ Greenville ∙ Wilmington ∙ Winston-Salem